These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 26423553)

  • 1. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.
    Nosyk B; Zang X; Min JE; Krebs E; Lima VD; Milloy MJ; Shoveller J; Barrios R; Harrigan PR; Kerr T; Wood E; Montaner JSG
    Lancet HIV; 2017 Jul; 4(7):e303-e310. PubMed ID: 28366707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013.
    Nosyk B; Min JE; Krebs E; Zang X; Compton M; Gustafson R; Barrios R; Montaner JSG;
    Clin Infect Dis; 2018 Feb; 66(5):765-777. PubMed ID: 29028964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.
    Zang X; Tang H; Min JE; Gu D; Montaner JS; Wu Z; Nosyk B
    PLoS One; 2016; 11(11):e0167308. PubMed ID: 27893864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.
    Zhang L; Phanuphak N; Henderson K; Nonenoy S; Srikaew S; Shattock AJ; Kerr CC; Omune B; van Griensven F; Osornprasop S; Oelrichs R; Ananworanich J; Wilson DP
    Lancet HIV; 2015 May; 2(5):e200-7. PubMed ID: 26423002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
    Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
    PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
    Alistar SS; Owens DK; Brandeau ML
    PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding access to HAART: a cost-effective approach for treating and preventing HIV.
    Johnston KM; Levy AR; Lima VD; Hogg RS; Tyndall MW; Gustafson P; Briggs A; Montaner JS
    AIDS; 2010 Jul; 24(12):1929-35. PubMed ID: 20588171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.
    Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ
    Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
    Alistar SS; Grant PM; Bendavid E
    BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
    AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of antiretroviral therapy expansion strategies in Vietnam.
    Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Reyes J; Doran C; Zhang L
    AIDS Patient Care STDS; 2014 Jul; 28(7):365-71. PubMed ID: 24983389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
    Montaner JS; Lima VD; Barrios R; Yip B; Wood E; Kerr T; Shannon K; Harrigan PR; Hogg RS; Daly P; Kendall P
    Lancet; 2010 Aug; 376(9740):532-9. PubMed ID: 20638713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.